Abstract | Lung cancer is the leading cause of cancer death worldwide, making it an attractive disease for chemoprevention. Although avoidance of tobacco use and smoking cessation will have the greatest impact on lung cancer development, chemoprevention could prove to be very effective, particularly in former smokers. Chemoprevention is the use of agents to reverse or inhibit carcinogenesis and has been successfully applied to other common malignancies. Despite prior studies in lung cancer chemoprevention failing to identify effective agents, we now have the ability to identify high-risk populations, and our understanding of lung tumour and premalignant biology continues to advance. There are distinct histological lesions that can be reproducibly graded as precursors of non-small-cell lung cancer and similar precursor lesions exist for adenocarcinoma. These premalignant lesions are being targeted by chemopreventive agents in current trials and will continue to be studied in the future. In addition, biomarkers that predict risk and response to targeted agents are being investigated and validated. In this Review, we discuss the principles of chemoprevention, data from preclinical models, completed clinical trials and observational studies, and describe new treatments for novel targeted pathways and future chemopreventive efforts.
Introduction
The term cancer chemoprevention was first introduced into the medical literature in 1976 by Michael Sporn and was defined to be the use of dietary or pharmaceutical interventions to slow or reverse the progression of pre malignancy to invasive cancer. In this landmark publi cation, 1 Sporn discussed the evidence supporting the potential efficacy of retinoids in preventing lung cancer, a hypothesis that has subsequently undergone significant clinical testing with largely null or harmful outcomes in patients. For cancer chemoprevention to succeed, a high risk population needs to be identifiable and agents that are both efficacious and associated with tolerable adverse effects must be available. For prevention of lung cancer, individuals at high risk can be readily identified using simple clinical features. 2, 3 Unfortunately, no pharmaco logical or dietary intervention has been demonstrated to reduce lung cancer risk. Smoking cessation is currently the only known intervention effective in reducing the risk of lung cancer. 4 Lung cancer is the leading cause of cancer death in the world, with an estimated 1,387,400 deaths in 2011, 5 making it an attractive target disease for cancer chemo prevention. In the USA, over 200,000 lung cancer diag noses were made in 2012 and the 5year overall survival for patients is a dismal 16%. 6 Although gradual improve ments in survival have been achieved, this advance has not matched those seen for other common malignancies, such as breast, prostate and colon cancer, partly as a result of lung cancer patients often presenting at an advanced stage where surgical cure is no longer feasible. Early detec tion is critical for improving outcomes, and lung cancer screening using lowdose CT scans has been shown to be effective in reducing mortality by 20%. 7 Although this is a major advance in preventing deaths from lung cancer, even with the widespread introduction of CT screen ing, overall survival remains low, with less than 20% of patients living beyond 5 years. Populations at high risk for lung cancer, with an annual incidence of up to a 2%, can be readily identified using easily obtainable informa tion, including smoking history, previous history of a tobaccoinduced cancer, pulmonary function, and family history. 3, 8, 9 More sophisticated risk assessment models have been developed, which include capacity for DNA repair, but these models do not add greatly to the previ ously described models. 9 For breast cancer, a predicted annual incidence of 0.3% is an indication for consideration of chemoprevention treatment, so the potential population for lung cancer chemoprevention is comparatively large.
The vast majority of lung cancers diagnosed in the USA (85-90%) are associated with exposure to tobacco smoke. 10 Therefore, prevention of smoking initiation is clearly the most effective intervention that can be applied to reduce the burden of lung cancer. Smoking cessation has been demonstrated to decrease lung cancer and prolong life. 4, 11 Most recently, this was shown in the Million Women Study in the UK, where female smokers who continued to smoke beyond the age of 40 lost at least 10 years of lifespan. 12 In contrast to other smoking related diseases, former heavy smokers retain a signifi cant risk of developing lung cancer years after smoking cessation. Currently in the USA, more than 50% of lung cancer occurs in former smokers. 13, 14 Studies have shown that response to chemopreventive agents may differ between current and former smokers, with a more favourable response in the latter. 15, 16 Therefore, limit ing chemoprevention clinical trial enrolment to former smokers or analysis of the two groups separately remains a reasonable strategy.
In this Review, we provide an overview of previous clinical trials that assessed lung cancer prevention as the primary goal. We will also discuss strategies for identi fying new agents for lung cancer prevention, including modulation of intermediate end point biomarkers, pre clinical models and observational studies. Finally, we will summarize our vision of novel ways to move the field forward.
Human pulmonary carcinogenesis
Lung cancer is currently divided into histological c lassifications of smallcell carcinoma and the nonsmall cell carcinoma types of adenocarcinoma, sq uamouscell carcinoma, and largecell undifferentiated carcinoma. Adenocarcinoma and squamouscell lung cancer make up the vast majority of lung cancer cases, and are the only cell types for which premalignant histology has been well characterized. For both of these subtypes of lung cancer, multistep carcinogenesis involving genetic and epigenetic alterations in pulmonary epithelial cells has been demonstrated. 17 However, a consistent progression of events has not been clearly established.
For squamouscell lung cancer, progression through a series of histological changes, which can be sampled by bronchoscopy, has been described. These changes, classified by the WHO, include reserve cell hyperplasia, squamous metaplasia, mild, moderate and severe dys plasia, and carcinoma in situ (Figure 1) . 18 The lesions can be reproducibly graded, 18 but the risk of progression of each lesion to invasive squamouscell lung cancer has not been well established because this process is dif ficult to study and, therefore, remains controversial. Several studies have suggested that assessment of the accumulation of genetic alterations-assessed by fluo rescence in situ hybridization (FISH), 19 PCRbased loss of hetero zygosity, 20 comparative genomic hybridization 21 or sequence analysis 22 -might provide important prog nostic information beyond that of the level of histo logical dysplasia. 23 Amplification of genes encoded on chromo some 3q26, 21 including SOX2, PIK3CA and TP63, has been identified as an early event in the development of squamouscell lung cancer, with SOX2 amplification occurring before the other genetic changes. 24 The premalignant biology of adenocarcinoma is more difficult to investigate than that of squamouscell lung cancer, since lesions are only accessible by surgical resec tion or percutaneous needle biopsy. Adenocarcinoma seems to be preceded by a premalignant lesion (atypical adenomatous hyperplasia) and the preinvasive lesion (adenocarcinoma in situ, formerly known as broncho alveolar carcinoma), which progresses to invasive adeno carcinoma. 25 In some cases, specific EGFR or KRAS mutations might precede the development of invasive squamous cell or adenocarcinoma. [26] [27] [28] In 1953, Slaughter et al. 29 introduced the term 'field c ancerization' to describe the frequent occurrence of widespread premalignant histological changes and second primary neoplasms in smokers with oral cancer. It is now widely accepted that field cancerization also occurs in the lower respiratory tract during pulmonary carcinogenesis, with the molecular correlates of widely dispersed epithelial cells harbouring mutations in either TP53 or EGFR associated with squamouscell or adeno carcinoma premalignancy, respectively. 22, 26 EGFR or p53 protein over expression has been reported in premalig nant dysplasia, 27, 30 and expression is most pronounced in moreadvanced lesions (that is, severe dysplasia and carcinoma in situ).
Chemoprevention
Carcinogenesis is a complex process, involving carcinoge n exposure and activation, DNA adduct formation, inflam mation, oxidative stress, mutation and epigenetic alter ations, which lead to the acquisition of the hallmarks of cancer. 31 These hallmarks include: sustained proliferative signalling; growth suppression evasion; cell death resis tance; replicative immortality; angiogenesis; invasion or metastasis; reprogrammed energy metabolism, and immune evasion. All these hallmarks arise as a result of genomic instability. Chemoprevention efforts have been directed at all of the carcinogenic processes, as well as at many of these intrinsic features of cancer ( Figure 1 ). Both adenocarcinoma and squamouscell carcinoma of the lung are genetically complex and heterogeneous, making chemoprevention with an agent targeted to specific driver mutations unlikely to be widely effective, except perhaps in the setting of definable premalignant lesions (ground glass opacities or endobronchial dysplasias) with estab lished mutations in targetable proteins. 32, 33 Loss of func tion of the p53 tumoursuppressor protein might be the most common mutation in squamous cell and adeno carcinoma, but approaches to restore p53 function have yet to be therapeutically translated. We speculate that the most broadly effective chemoprevention approaches will focusing on frequently altered pathways may be a promising strategy because molecular targeting of chemoprevention to specific mutations is challenging ■ Chemoprevention targeted to phenotypes expressing specific carcinogenic influences, including inflammation, angiogenesis, hypoxia and epithelial differentiation, appears most likely to succeedphenotypes target general processes, such as suppression of inflam mation, interference with autocrine or paracrine growth stimulation, restoration of epithelial differentiation and polarity, augmentation of apoptosis, improved immune surveillanc e, and suppression of invasion or angiogenesis.
Phase III chemoprevention trials Chemoprevention efforts fall into three distinct sub groups: primary, secondary and tertiary. Primary chemo prevention involves patients at increased risk, but without a previous history of cancer. Secondary chemo prevention studies enroll individuals with increased risk and evidence of premalignancy. For lung cancer, this usually refers to sputum cytological atypia and/or endobronchial dysplasia. Recent studies have also focused on individuals with ground glass opacities on CT scan suggestive of adenocarcinoma in situ or atypical adeno matous hyperplasia. [34] [35] [36] Tertiary chemoprevention trials have the end point of a second primary tumour in indivi duals with a previous tobaccoinduced aero digestive cancer. A number of phase III chemoprevention trials, including primary, secondary and tertiary studies, have been reported in the past two decades (Table 1) . Unfortunately, the results of phase III lung cancer chemoprevention trials can be summarized succinctly: aspirin, [37] [38] [39] retinyl palmitate, 40 13cisretinoic acid, 41 vitamin E, 42 a multivitamin and mineral supplement, 43 and selenium 44 are all ineffective; betacarotene seems to be harmful in current smokers. 16 As the discouraging results of phase III lung cancer chemoprevention trials have accumulated, investigators and funding agencies have adopted increasingly stringent criteria for assessing a treatment in a phase III trial. 45 Although all criteria cannot be applied to every putative agent, evidence supporting efficacy of a chemo preventive intervention ideally should be derived from multiple sources, including mechanistic, preclinical, observational and phase II studies with intermediate or surrogate end points. In addition, ideal chemopreventive agents would be well tolerated, inexpensive, and perhaps also treat comorbid disease (such as chronic obstructive pulmo nary disease [COPD] , diabetes mellitus, pulmonary hypertension, or atherosclerosis) in highrisk indivi duals. Currently, no interventions other than smoking cessation have been shown to reduce lung cancer risk, so we believe that efficacy should take precedence over these ancillary characteristics as attempts are made to discover ways to reduce lung cancer risk. Early phase trials Although phase III clinical trials represent the definitive means of demonstrating efficacy in terms of reducing cancer incidence and mortality, phase II cancer preven tion trials rely on intermediate end points that are meant to predict these outcomes. The terms 'surrogate end point' and 'intermediate end point' are not synonymous. A surro gate end point is obtained earlier, potentially less invasively, and at lower cost than a true end point, but serves as a substitute for the true outcome. An inter mediate end point should be integrally involved in the disease process (carcinogenesis in this case), and expres sion should differ between normal and atrisk s ubjects and correlate with disease course. 46 Owing to the lack of an effective chemopreventio n agent for lung cancer ( 18 Whether an effect on these squa mous precursor lesions might carry over to premalignant adeno carcinoma lesions is speculative. The complexity of branching airway anatomy and small calibre of higher division airways makes broncho scopic inspection of the entire epithelial surface impossible. It is extremely rare to biopsy a premalignant dysplasia that subsequently devel ops into an invasive squamouscell carci noma, so accu rately predicting the progression of premalignant lesions (except possibly for carcinoma in situ) is infrequent and controversial. Although endobronchial histology has a poor correlation with lung cancer risk, the addition of biomarkers of genetic alteration (including chromo somal aneusomy detected by FISH, PCRdetected loss of hetero zygosity or genecopy number changes detected by comparative genomic hybridization or single nucleotide polymorphism array) are promising. [19] [20] [21] [22] Proliferation index, most commonly measured by Ki67 immuno staining, is a similarly plausible, but unvalidated inter mediate end point biomarker. 48 A number of novel biomarkers have been developed that might be vali dated and could be used in phase II chemoprevention trials. These include a transcriptomic signature derived from endobronchial or nasal brushings, 49, 50 biopsy pro teomics, 51 serum proteomics, 52 and the a nalysis of v olatile organic c ompounds in exhaled breath. 53 Several phase II chemoprevention trials have been completed (Table 2 ), although few have met their primary end point. Two negative phase II trials of 13cis retinoic acid, with histological end points, 54, 55 have been published and the results are consistent with the nega tive phase III trial of 13cisretinoic acid in individuals with a previous lung cancer diagnosis. 41 This consistency at least suggests that phase II trials might help identify potential chemopreventive agents that should not pro gress to phase III testing. To date, the only trials to have met the primary end point are those assessing iloprost (a drug to treat pulmo nary arterial hypertension that produced histological improvement 56 ) and celecoxib (decreased Ki67 levels in two trials 57, 58 ). In the iloprost trial, Ki67 level was a secondary end point and was not decreased by iloprost treatment. However, there were considerable differences between the celecoxib and ilo prost trials. In the celecoxib trials, dysplasia was either extremely infrequent or not reported, and the iloprost trial evaluated a cohort with an approximately 70% inci dence of dysplasia. Expression of Ki67 was assessed largely in the normal bronchial epi thelium in the cele coxib trials and in moreadvanced lesions in the iloprost trial. As no inter mediate end points have yet been vali dated to be predictive of chemo preventive efficacy, it is not clear if either the modulation of histology or Ki67 index is informative.
Although most phase II trials have assessed histologica l or proliferative intermediate end points in the central airways, three trials evaluated CTdetected pulmonary nodules in response to inhaled cortico steroids. [34] [35] [36] CTdetected nodules were not the primary end point in two of these trials, but were included in exploratory analy ses that indicated efficacy of inhaled cortico steroids, and led to a third trial with nodules as the primary end point. The latter trial, 34 was negative in that nodules were not decreased by inhaled corticosteroids. This poten tially exciting new end point might represent atypical adenomatous hyperplasia or adenocarcinoma in situ, which presents as ground glass opacities on t horacic CT scan. However, this end point lacks specificit y as other pulmonary conditions, including infection, organizing pneumonia, hypersensitivity pneumon itis, and desqua mative interstitial pneumonia, can also cause ground glass opacities. 59 Shortterm trials assessing the response of the ground glass component of semisolid pulmonary nodules that will undergo resection might address this lack of specificity, but we are not aware of any such trials that are ongoing or planned.
The phase I trial that assessed myoinositol had no control group, but gave promising results when compared REVIEWS to historical controls. 60 Of interest, geneexpressio n profiling of bronchial brushings identified increased expression of PI3K in association with lung cancer or dysplastic lesions. 61 Myoinositol inhibits PI3K, and elevated expression of genes involved in PI3K signalling identified patients who responded to myoinositol. These data indicate that the personalization of chemoprevention may be possible, as is the case for treating lung cancer with targeted agents. 61 Results of an ongoing random ized c ontrolled phase II trial of myoinositol will be of great interest.
Preclinical studies Similar to other common cancers, animal models of nonsmallcell lung cancer have been extensively used to study lung carcinogenesis and perform preclinical studies involving chemopreventive agents. Multiple, well characterized models of murine adenocarcinoma are available, including initiatorpromoter carcino genesis, 62 mutant KRAS 63 or EGFR 64 and the use of complete carcino gens. [65] [66] [67] Tobacco smoke is a mouse lung carcino gen and can reproducibly induce pulmonary adeno carcinomas, but it is a labourintensive and expensive model. 68 More recently, a chemically induced sq uamous cell lung carcinoma model has been described, and histo pathological analysis of serial lung sections in this model revealed a range of lung pathology, including squamous cell carci noma, carcinoma in situ, and varying levels of bronchial dysplasia. 69 Immunohistochemical studies on the premalignant lesions show staining that corresponds to analogous human lesions. 70 Gene expression similari ties between human and murine adeno carcinoma have been described; 71 these comparisons have not yet been made for the squamouscell carcinoma model.
Eicosanoids represent a large family of bioactive lipid molecules that signal through autocrine and paracrine pathways and have been implicated in cancer initiation, progression and metastasis (Figure 2) . 72 Prostaglandin I 2 (PGI 2 , prostacyclin) is a member of the eicosanoid family that has antiinflammatory, anti proliferative, anti metastatic, and potent chemopreventive properties. 73 The chemo preventive effects of PGI 2 , or its analogue iloprost, are independent of the canonical cell surface receptor (prostacyclin receptor), but rather involve the activation of the nuclear receptor peroxisome proliferator activated receptor gamma (PPARγ). 74 PPARγ ligands inhibit the growth of lung cancer cell lines in vitro and in xenograft models, resulting in decreased proliferation, increased apoptosis, and promotion of differentiation (which may allow for the use of targeted therapeutics). 75, 76 Furthermore, multiple animal carcinogenesis studies have demonstrated that PPARγ ligand treatment inhibits lung tumour development and can induce apop tosis. 77, 78 The observed tumour inhibition occurs in the setting of mutated TP53, thereby mirroring the most common human genetic abnormality found in lung cancer. The addition of the PPARγ ligand pioglitazone to the inhaled steroid budesonide further improved the effi cacy associated with either agent alone and was shown to decrease tumour load by 90% in animals exposed to the cigarette smoke carcinogen benzo(a)pyrene. 78, 79 Mice over expressing lungspecific PPARγ developed 70% fewer tumours than wildtype controls when exposed to carcinogens. 74 Chemopreventive interventions have been assessed in murine preclinical models. Inhaled and systemic gluco corticoids, 80 myoinositol, 80 overexpression of PGI 2 , 81 dietary administration of iloprost, 74 overexpression of PPARγ, 74 dietary administration of pioglitazone 78 and the VEGF inhibitor vandetanib, 82 as well as the anti oestrog en fulvestrant, have all proved efficacious in murine models. 83 The effect of COX inhibitors on lung cancer prevention has also been tested in murine models. The COX inhibitor indomethacin was found to be effec tive, 84 but the COX2 selective inhibitor celecoxib was not. 85 Additionally, rexinoids, agents that activate nuclear retinoid X receptors, and triterpenoids 86 have been shown to prevent murine adenocarcinoma, both alone and when used in combination. 87, 88 Observational studies Observational studies on the relationship of aspirin use and lung cancer are inconsistent; any positive reports are at odds with the results of randomized controlled studies including the Physicians' Health Study 37 and Women's Health Study. 38 Recently, a metaanalysis of casecontro l and cohort studies of aspirin in the prevention of vascu lar events was published in which the association between aspirin use and the incidence of several cancers was analysed. Regular use of aspirin was associated with a reduced risk of colorectal cancer (odds ratio = 0.62, 95% CI 0.58-0.67; P <0.0001), but only a trend towards pro tection from lung cancer was identified. 89 Another meta analysis of 15 observational studies (six casecontrol studies and nine prospective cohort studies) also failed to demonstrate a protective effect of aspirin for the preven tion of lung cancer. 90 A third metaanalysis of random ized controlled studies of daily aspirin versus no aspirin for the prevention of vascular events in which individual patient data on risk of cancer death was available yielded interesting results. 91 The 20year risk of death from lung cancer was significantly decreased in trials with sched uled aspirin treatment for 5 years or longer, with hazard ratios (HR) of around 0.70. This effect was entirely due to a reduction in deaths from adenocarcinoma and was seen only in longerduration studies (5 years or more) with longterm follow up. Although these studies are not definitive, they do raise the hypothesis that to demon strate the chemopreventive effect of aspirin on lung cancer, more than 5 years of treatment and longterm follow up might be needed.
Pulmonary inflammation is thought to be one factor leading to lung cancer. Therefore, it is perhaps not surprising that systemic and inhaled treatment with the antiinflammatory agents corticosteroids have chemo preventive efficacy in murine models. 80 A cohort study of patients being treated in Department of Veterans Affairs outpatient clinics reported that those receiving highdose inhaled corticosteroids and exhibiting good compliance had a reduced risk of lung cancer (HR = 0.39, 95% CI 0.16-0.96) compared to controls. 92 These results are in agreement with a metaanalysis of interventional studies of inhaled corticosteroids assessing COPD outcomes in which a trend towards protection from lung cancer mor tality (HR = 0.47, 95% CI 0.22-1.00) was noted (D. Sin, personal communication). The short period of obser vation of these trials (mean 26 months) limits their a pplicability to lung cancer chemoprevention.
The thiazolidinedione class of antidiabetic agents, including rosiglitazone and pioglitazone, act through the PPARγ nuclear receptor, as does the prostacyclin analogue iloprost. 74 Two large observational studies Figure 2 | Schematic pathway of the cyclooxygenase pathway showing conversion of arachidonic acid to prostanoids. The fatty acid arachidonic acid is released from the membrane phospholipids by several forms of phospholipase A 2 , which have previously been activated by one of a range of stimuli. The free arachidonic acid is converted to the cyclic endoperoxides prostaglandin G 2 and prostaglandin H 2 by the sequential COX and HOX actions of PGHS-1 or PGHS-2; these isoforms both have dual COX and HOX activity. Aspirin inhibits the conversion of free arachidonic acid to prostaglandin G 2 by inhibiting the COX activity of PGHS-1 or PGHS-2. Prostaglandin H 2 is converted into a range of prostanoids by tissue-specific isomerases; therefore, the inhibition of this pathway prevents (or reduces) the downstream activation of a superfamily of G-protein-coupled receptors by these prostanoids. Prostacyclin binds to both a transmembrane G-protein coupled receptor and to PPARγ, a nuclear receptor. Abbreviations: ASA, acetylsalicylic acid; COX, cyclooxygenase; HOX, hydroperoxidase; NSAIDs, nonsteroidal anti-inflammatory drugs; PGHS, prostaglandin H synthase; PPARγ, peroxisome proliferator-activated receptor γ.
have compared lung cancer incidence in patients with type II diabetes mellitus treated with thiazolidinediones versus other agents, and both have reported an approxi mate 33% reduction in lung cancer risk (P = 0.003-0.001) in the thiazolidinedionetreated patients. 93, 94 However, a third large cohort study from the Kaiser Permanente Northern California Diabetes Registry did not find an association between the use of pioglitazone and decreased risk of lung cancer. 95 There has been considerable interest in the anti diabete s agent metformin as a cancer chemoprevention agent. One of the previously described analyses also evaluated metformin use and found a protective effect similar (20-50%, P = 0.001) to that observed with the thiazolidinediones. 94 However, published observational studies examining the association between metformin use and lung cancer risk have had mixed results, with two studies reporting that metformin does not have a protec tive effect. [96] [97] [98] By contrast, two systematic reviews and metaanalyses have concluded that the use of metformin in patients with type II diabetes mellitus is associated with significantly lower risk of lung cancer incidence. 99, 100 Metformin has also been demonstrated to be chemo preventive in preclinical models. 101 Putative mechanisms for a chemopreventive effect include decreased levels of insulin and insulinlike growth factor and energy stress leading to inhibition of liver kinase B1 (LKB1)/AMP activated protein kinase (AMPK) signalling. 102 The role of oestrogen in lung carcinogenesis has attracted considerable attention. 103 In the Women's Health Initiative randomized controlled trial, use of oestro gen plus progestin resulted in increased lung cancer mor tality. 104 However, use of oestrogen alone in the same study did not increase either incidence or death from lung cancer. 105 An observational study of the California Teachers Study cohort found no association between either oestrogen or oestrogen plus progestin and the risk of lung cancer. 106 A second study of the NIHAARP Diet and Health Study cohort also found a similar lack of associ ation between oestrogen or oestrogen plus pro gestin and lung cancer risk. 107 The aromatase inhibitor exemestane was compared to the antioestrogen tamoxi fen in a randomized controlled trial of women with breast cancer who had been treated for 2-3 years with tamoxi fen. 108, 109 Exemestane treatment resulted in significantly improved breast cancer diseasefree survival and there were fewer lung cancer deaths (4 versus 12) in the exemes tane group compared to the tamoxifen group. However, this did not achieve statistical significance owing to the small number of events. Thus, although there is some tantalizing data from both preclinical and clinical studies that treatment with aromatase inhibitors might prevent lung cancer, further investigation is needed.
Finally, a large number of epidemiological studies assessing the relationship between diet and lung cancer incidence have been performed. Almost universally, these demonstrate an inverse correlation between diets that are high in fruit and vegetables and lung cancer incidence. 110 Whether this association represents a true protective action or is the result of other variables associated with fruit and vegetable intake is unclear because no inter ventional studies have been reported in which dietary manipulations have reduced the incidence of lung cancer.
Future chemoprevention efforts
Agents that have now been clearly shown to lack promise in lung cancer chemoprevention trials, based on null or harmful results in phase III trials, include betacarotene, aspirin, retinol, multivitamin and mineral supplements, vitamin E, retinyl palmitate, 13cisretinoic acid, Nacetyl cysteine and selenium (Table 1) . Several of these agents are dietary antioxidants, making the general approach of antioxidant administration unattractive without further data supporting efficacy. Aspirin has had nega tive results in phase III trials, but a recent metaanalysis of randomized trials of aspirin for prevention of vascu lar events suggests that an intervention period of 5 years or more and prolonged follow up might be necessary to de monstrate a reduction in lung cancer risk. 91 Chemoprevention agents currently under investigatio n that have substantial support for incorporation into phase III trials are limited. Inhaled corticosteroids might be the lead agent class because their use is supported by positive data from observational and preclinical studies. However, phase II trials assessing these agents with end points of either dysplasia or nodule growth have been negative, 35 although the lack of specificity surrounding the use of pulmonary nodules as an intermediate end point softens this negative factor. Inhaled corticosteroids are currently used as a treatment for patients with COPD, which is an independent risk factor for lung cancer. 111 Phase III trials with COPDspecific end points have not shown a robust reduction in lung cancer incidence, but the design of these trials, with an average followup period of only 26 months, is not ideal for the assessment of cancer chemoprevention. [112] [113] [114] Consideration should be given to the initiation of a phase III chemoprevention trial of inhaled corticosteroids for the prevention of lung cancer with a longer duration.
The use of the antidiabetic agents pioglitazone and metformin for chemoprevention is also supported by both preclinical and observational studies (albeit with mixed results). A phase II trial of pioglitazone or placebo with the end point of dysplasia is currently underway.
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Prostacyclin analogues, specifically iloprost, act through the same PPARγ nuclear receptor as pioglitazone and other thiazolidinediones, 116 so there is some observa tional support for these agents. In addition, iloprost is effective in preclinical experiments and is the only agent to have demonstrated improvement in endobronchial dysplasia in a phase II trial. The next step to assess the effectiveness of iloprost for chemoprevention would be longer term trials with lung cancer as an end point.
Improved methods for risk assessment, beyond the current models based on clinical and demographic character istics, would allow chemoprevention trials to be more efficiently designed. 2, 3, 9 While the current models may be improved by the incorporation of genetics or biomarkers, specific markers have not been validated as providing a major improvement in risk assessment.
Furthermore, the currently available risk models allow the identification of individuals with approximately a 2% yearly risk of developing lung cancer. Currently, the field of lung cancer chemo prevention is more in need of the development of new agents than improved risk models.
Clearly, the translation of preclinical findings into c linically effective chemoprevention of lung cancer has been difficult and largely disappointing. Highthroughput screening and functional genomics 117 could be used to identify new promising approaches for chemo prevention, but we are not aware of such applications to date. As lung carcinogenesis is a complex, multi step process involv ing both the epithelium and stroma, new approaches for lung cancer chemoprevention will still need to be evalu ated in preclinical animal models and ultimately in the clinical setting.
The lung is a unique organ, in that there is a long history of therapeutic agents being administered via the inhalational route. Inhalational administration can be more effective than systemic administration and mini mizes adverse effects. 118 The potential use of inhaled agents in early phase chemoprevention trials does raise some issues regarding the necessity for and interpreta tion of traditional end points, such as blood levels of drug. With the exception of inhaled corticosteroids, we are not aware of clinical trials using inhaled agents for lung cancer chemoprevention. [34] [35] [36] Furthermore, inhaled treatment in preclinical models is difficult and often results in different patterns of drug distribution compared to those seen in humans. 119 However, inhaled chemoprevention is an attractive approach going forward as it maximizes drug delivery to the target organ and minimizes systemic effects. 118 Personalized medicine has been exemplified by the success of targeted therapy in treating molecularly defined subsets of patients, most commonly with specific driver mutations. The complexity of genetic mutations in both adenocarcinoma and squamouscell lung cancer, 32, 33 coupled with the difficulty in detecting and analysing premalignant lesions, are challenges to personalized chemo prevention for lung cancer. It might be possible to define common pathways in early carcinogenesis, such as PI3K activation or p53 inactivation, which are shared by significant fractions of the atrisk population and might be targeted in a directed fashion provided effec tive agents are identified. Myoinositol has been proposed as an agent that may be useful for targeting individuals specifically with premalignant lesions characterized by activated PI3K signalling, and an ongoing trial is testing this hypothesis. 61 Alternately, phenotypes such as airway or parenchymal inflammation, incipient angiogenesis, tissue hypoxia, or excessive growth factor expression, might be defined, each of which would respond best to a different intervention. 82, 120, 121 
Conclusions
Lung cancer is the leading cause of death from cancer worldwide and a disease for which highrisk individu als can be readily identified. Even after smoking cessa tion is accomplished, former smokers are at significant residual risk of developing lung cancer. These factors make lung cancer an ideal target for chemo prevention. Attempts to discover and validate chemo preventive agents have been frustrating; however, there are a number of interesting compounds that might be effec tive. These include inhaled glucocorticoids, myoino sitol, prostacyclin analogues and thiazolidinediones. Advances in driver mutation targeted treatment of lung cancer might provide insight into targets and potential chemotherapeutic agents for future trials. Personalized chemoprevention is likely to be targeted more to pheno types, such as airway inflammation, alveolar hypoxia, or incipient angiogenesis, than to specific driver muta tions. Validating biomarkers of risk and response will be c ritical to advancing the field.
Review criteria
The PubMed database was searched for articles with no restriction on date. The search terms used included: "lung cancer", "chemoprevention", "animal models", and the various chemopreventive agents in past and current trials (summarized in Tables 1 and 2 ), "trials", "biomarkers", "tobacco smoke", "pre-malignant airway lesions" and "carcinogenesis". Only articles published in English were considered, and the final PubMed search was conducted on 2 April 2013.
